March 15, 2011

Five senators have issued a letter to Food and Drug Administration commissioner Margaret Hamburg to expand Americans' access to affordable medications by avoiding the delay of generic drug approvals.

February 18, 2011

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


February 18, 2011

A drug used to treat high cholesterol, which will lose patent protection and face generic competition starting this year, also may help prevent blindness in people with diabetes, according to a study by researchers at the University of Georgia.

February 4, 2011

The cardiovascular drug market will turn into a difficult conquest in the years to come as it increasingly will be dominated by generics, but that isn’t stopping drug companies from continuing to develop treatments — 299 of them, according to a recent report by the Pharmaceutical Research and Manufacturers of America — for high cholesterol, hypertension, atrial fibrillation, heart failure and other heart-related conditions.

January 25, 2011

Generic drug maker Mylan has entered settlements with Pfizer concerning two drugs for treating cholesterol.

January 5, 2011

A generic version of the world’s top-selling cholesterol treatment is expected to hit the market this year, but the branded version’s manufacturer is trying to put the brakes on the launch, according to media reports.

November 14, 2010

The world of generic drugs has a big year ahead of it. Actually, it has...

September 26, 2010

Winc Design is launching its Charlie Banana brand of environmentally friendly cloth diapers and baby...

August 30, 2010

The U.S. drug market will present opportunities as well as uncertainties over the next decade,...

October 18, 2009

What’s really intriguing behind the return of a consumer division to Pfizer is the fact...